NCT06899178View on ClinicalTrials.gov

Atomoxetine in Melanocortin Obesity Syndrome

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Melanocortin Obesity SyndromeMCOS
Interventions
DRUG

Atomoxetine

Initial dose 40 mg, day 7 dose 60 mg, day 14 dose 80 mg, day 21 dose 100 mg (target dose)

DRUG

Placebo

Matching placebo oral capsule

Trial Locations (2)

10029

Mount Sinai Hospital, New York

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

Vanderbilt University Medical Center

OTHER

lead

Icahn School of Medicine at Mount Sinai

OTHER